alg13 Antibody

What is ALG13 and why is it important in research?

ALG13 is an essential enzyme involved in protein glycosylation, specifically in the N-linked glycosylation pathway. It forms a heterodimeric complex with ALG14 to create a UDP-N-acetylglucosamine transferase (GnTase) that catalyzes the second step of eukaryotic lipid-linked oligosaccharide (LLO) biosynthesis . This process is critical for proper protein folding, stability, and function.

Research on ALG13 is important because dysregulation of protein glycosylation has been linked to various diseases, including congenital disorders of glycosylation (CDG) and cancer . In humans, mutations in ALG13 or ALG14 lead to severe neurological disorders with a multisystem phenotype, known as ALG13/14-CDG . Understanding ALG13's role can provide insight into potential therapeutic targets for these conditions and advance our knowledge of glycosylation pathways and their role in various biological processes .

What applications is the ALG13 antibody suitable for?

Based on the available data, the ALG13 Polyclonal Antibody (e.g., CAB18115) is specifically designed for Western blot applications with a recommended dilution range of 1:500 - 1:2000 . It shows reactivity with human and mouse samples and can be used to detect ALG13 expression in various cell types including Raji, K-562, Jurkat, HepG2, mouse liver, and mouse kidney tissues .

This antibody is valuable for research in fields such as glycobiology, developmental biology, and disease mechanism studies . By targeting the ALG13 protein, this antibody allows for accurate detection and analysis of ALG13 expression in various cell types, facilitating research in essential biological processes related to protein glycosylation .

How should ALG13 antibody be stored and handled?

The ALG13 antibody should be stored at -20°C and freeze/thaw cycles should be avoided to maintain its effectiveness . The storage buffer typically consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . This formulation helps maintain antibody stability during long-term storage.

When handling the antibody, standard laboratory safety practices should be followed, particularly given the presence of sodium azide in the storage buffer. For optimal results in Western blot applications, the antibody should be diluted in an appropriate buffer according to the recommended range (1:500 - 1:2000) just before use .

What are the different isoforms of ALG13 and how do they function?

There are at least two isoforms of human ALG13: isoform 1 (longer) and isoform 2 (shorter). According to research findings, only the shorter ALG13 isoform 2 forms a functional complex with ALG14 that participates in LLO synthesis . The longer ALG13 isoform 1 does not form a complex with ALG14 and therefore lacks GnTase activity .

This functional difference between isoforms has been demonstrated through various experimental approaches, including co-immunoprecipitation and GnTase activity assays . When HA-ALG13-iso1 and FLAG-ALG14 were co-expressed in HEK293 cells, FLAG-ALG14 completely failed to coprecipitate with HA-ALG13-iso1, while it efficiently interacted with HA-tagged ALG13-iso2 . This distinction is crucial for research design as experiments targeting ALG13 function should focus on isoform 2.

How can I distinguish between ALG13 isoforms using antibodies?

To distinguish between ALG13 isoforms in research settings, several approaches can be employed:

• Tag-based detection: As demonstrated in the literature, researchers have successfully used HA-tagged ALG13 isoforms expressed in cells and detected them using anti-HA antibodies . This approach allows for specific identification of each isoform when combined with SDS-PAGE to separate them by size.

• Isoform-specific antibodies: Though not explicitly mentioned in the search results, antibodies that recognize unique regions of each isoform could be developed for direct detection of endogenous isoforms.

• Functional assays: To confirm the identity of each isoform, functional assays such as co-immunoprecipitation with ALG14 can be performed, as only isoform 2 forms a complex with ALG14 . This provides a functional distinction between the isoforms.

• Western blotting with size discrimination: The different molecular weights of the isoforms can be leveraged in Western blot analysis, with isoform 1 being longer than isoform 2, resulting in different migration patterns on SDS-PAGE .

What experimental approaches can be used to study ALG13/ALG14 complex formation?

The ALG13/ALG14 complex formation can be studied using several experimental approaches:

• Co-immunoprecipitation (Co-IP): This is the primary method described in the search results. Co-express tagged versions of ALG13 and ALG14 (e.g., HA-tagged ALG13 and FLAG-tagged ALG14) in cells such as HEK293 . After extracting membrane proteins with detergent (1% Triton X-100), immunoprecipitate one protein using the corresponding antibody (e.g., anti-HA antibody for HA-ALG13), and detect the co-precipitation of the other protein by immunoblotting with the appropriate antibody (e.g., anti-FLAG antibody for FLAG-ALG14) .

• Bacterial co-expression systems: E. coli Rosetta cells (DE3) harboring both pET26b-pelB-FLAG-ALG13-iso2 and pCDFDuet-6His-ALG14 plasmids can be used to express and purify the complex . This system allows for large-scale production of the complex for functional studies.

• Functional GnTase assays: Since heterodimer formation is essential for ALG13/14 GnTase activity, enzymatic activity assays can indirectly confirm complex formation . The complex can be reconstituted in vitro using purified components and tested for activity using the GnTase assay described in the literature.

How can I measure ALG13/ALG14 GnTase activity in vitro?

The literature describes a liquid chromatography/mass spectrometry-based quantitative GnTase assay for measuring ALG13/ALG14 activity:

• Substrate preparation: Use chemically synthesized GlcNAc-pyrophosphate-dolichol (Gn-PDol) as the acceptor substrate and UDP-GlcNAc as the donor .

• Reaction setup: Prepare a standard reaction mixture containing:

  • 28 mM Tris/HCl, pH 7.5

  • 0.3% NP-40

  • 23% glycerol

  • 40 μM Gn-PDol

  • 2 mM UDP-GlcNAc

  • Purified ALG13/ALG14 complex or membrane fraction containing the complex

• Incubation: Incubate the reaction mixture at 37°C for an appropriate time period .

• Reaction termination: Stop the reaction by heating to 100°C .

• Analysis: Add hydrochloric acid to hydrolyze the saccharide moieties, followed by purification and detection using LC-MS for quantitative analysis . The conversion rate is quantified by calculating the peaks intensity of Gn2 (two peaks)/peak intensity of (Gn + Gn2) .

This assay has been successfully used to demonstrate that only ALG13 isoform 2, but not isoform 1, forms a functional complex with ALG14 that has GnTase activity .

How can I study ALG13 mutations associated with congenital disorders of glycosylation?

Research on ALG13 mutations associated with congenital disorders of glycosylation (CDG) can be approached through several methodologies:

• Enzymatic activity assays: The GnTase assay described above can be used to assess the functional impact of ALG13 mutations . This allows for quantitative measurement of how specific mutations affect enzymatic activity.

• Complex formation analysis: Using co-immunoprecipitation assays, researchers can determine whether mutations in ALG13 affect its ability to form a complex with ALG14, which is essential for GnTase activity .

• Expression systems: Both bacterial (E. coli) and mammalian (HEK293) expression systems have been used to produce wild-type and mutant ALG13 proteins for functional studies .

• Variant allele testing: The research demonstrates that GnTase activity assays can be applied to test variant alleles associated with ALG13-CDG . These variants display severe enzymatic deficiencies, confirming that GnTase deficiency is the cause of ALG13-CDG phenotypes .

What are the optimal conditions for Western blot analysis with ALG13 antibody?

For optimal Western blot analysis with ALG13 antibody, consider the following protocol elements:

• Sample preparation: Extract proteins using appropriate buffers containing detergents like Triton X-100 (1%) to solubilize membrane-associated proteins .

• Gel electrophoresis: Use 12% SDS-PAGE for good resolution of ALG13 protein . Load approximately 10 μg of protein extract per lane.

• Transfer: Transfer proteins to a PVDF membrane using standard transfer conditions .

• Blocking: Block the membrane with an appropriate blocking solution to reduce non-specific binding.

• Primary antibody: Incubate with ALG13 antibody at a dilution between 1:500 and 1:2000 . For commercial antibodies like CAB18115, follow the manufacturer's recommended dilution.

• Secondary antibody: Use an appropriate HRP-conjugated secondary antibody matching the host species of the primary antibody (e.g., anti-rabbit IgG-HRP conjugate for rabbit-derived ALG13 antibody) .

• Detection: Visualize immunoreactive bands using chemiluminescence (ECL) detection .

• Positive controls: Include cell lines known to express ALG13, such as Raji, K-562, Jurkat, and HepG2, as well as mouse liver and mouse kidney tissues .

What are the best approaches for co-immunoprecipitation experiments with ALG13 antibody?

For successful co-immunoprecipitation experiments with ALG13 antibody:

• Expression system: HEK293 cells have been successfully used for co-expression of tagged ALG13 and ALG14 proteins .

• Protein extraction: Harvest and resuspend cells in an appropriate buffer (e.g., HEPES buffer) containing 1% Triton X-100 to solubilize membrane proteins . Incubate on ice for 30 minutes to enhance solubilization.

• Immunoprecipitation: For tagged proteins, use antibodies against the tag. For example, anti-HA antibodies can be used to immunoprecipitate HA-tagged ALG13 . Incubate the protein extract with the antibody and Protein A+G Agarose beads to pull down the protein of interest .

• Washing: Wash the immunoprecipitated complex multiple times (e.g., 3 times) with buffer to remove non-specifically bound proteins .

• Analysis: Solubilize the immunoprecipitate, separate by SDS-PAGE, and analyze by Western blotting with appropriate antibodies to detect co-immunoprecipitated proteins .

• Controls: Include appropriate controls, such as immunoprecipitation with non-specific antibodies or analysis of non-interacting proteins, to validate the specificity of the observed interactions.

How can I optimize protein expression and purification for ALG13 functional studies?

For optimal protein expression and purification for ALG13 functional studies:

• Bacterial expression:

  • Use E. coli Rosetta cells (DE3) harboring plasmids encoding tagged versions of ALG13 and ALG14 .

  • Culture in rich media like Terrific-Broth at 37°C until OD600 reaches 1.0, then cool to 16°C .

  • Induce protein expression with 0.1 mM IPTG and incubate for 18-24 hours at 16°C .

  • Harvest cells and prepare crude extract by sonication in an appropriate buffer .

  • Obtain membrane fraction by centrifugation and solubilize with detergent (1% Triton X-100) .

• Mammalian expression:

  • Express tagged ALG13 in HEK293 cells .

  • Harvest cells and prepare protein extract using appropriate buffers containing detergent .

  • For immunoprecipitation-based purification, incubate the extract with specific antibodies and Protein A+G Agarose .

• Purification considerations:

  • For bacterial systems, use affinity chromatography based on the tags (e.g., His-tag, FLAG-tag) for initial purification .

  • For mammalian systems, immunoprecipitation with antibodies against the tag can be used .

  • Consider additional purification steps if higher purity is required.

  • Verify the integrity and activity of purified proteins before functional studies.

What might cause negative or weak signals in Western blot with ALG13 antibody?

Several factors might contribute to negative or weak signals when using ALG13 antibody in Western blot experiments:

• Antibody concentration: The dilution might be too high; try using a more concentrated antibody solution within the recommended range (e.g., 1:500 instead of 1:2000) .

• Protein expression levels: ALG13 might be expressed at low levels in your samples. Include positive control samples such as Raji, K-562, Jurkat, or HepG2 cells, which are known to express ALG13 .

• Protein extraction efficiency: Ensure your extraction method effectively solubilizes membrane-associated proteins, as ALG13 functions at the ER membrane . Using detergents like Triton X-100 (1%) can improve extraction .

• Isoform specificity: Verify whether the antibody recognizes the specific ALG13 isoform you are studying. Some antibodies might preferentially detect certain isoforms or regions of ALG13 .

• Detection system sensitivity: Check that your secondary antibody and ECL reagents are working properly and have not degraded over time. Fresh reagents might improve signal detection.

How can I resolve issues with ALG13/ALG14 complex formation in experimental settings?

If experiencing difficulties with ALG13/ALG14 complex formation in your experiments, consider these approaches:

• Isoform selection: Ensure you are using ALG13 isoform 2, as research clearly demonstrates that isoform 1 does not form a complex with ALG14 . This is a critical consideration that could explain failed complex formation attempts.

• Detergent optimization: Use a mild detergent like 1% Triton X-100 for membrane protein solubilization to preserve protein-protein interactions . Different detergents or concentrations might affect complex stability.

• Expression system: Both bacterial and mammalian expression systems have been successfully used for ALG13/ALG14 complex formation . Consider testing both systems if one proves challenging.

• Co-expression strategy: Co-express both proteins simultaneously rather than attempting to mix them after separate expression. The co-expression in E. coli Rosetta cells or HEK293 cells has been demonstrated to yield functional complexes .

• Tags and fusion proteins: The position and nature of protein tags might influence complex formation. The literature describes successful use of FLAG-tagged ALG13-iso2 and 6His-tagged ALG14 .

What factors affect ALG13/ALG14 GnTase activity assay results?

Several factors can influence the outcomes of ALG13/ALG14 GnTase activity assays:

• Enzyme quality and quantity: The activity of purified ALG13/ALG14 complex can vary between preparations. Ensure consistent purification protocols and quantify protein concentration accurately before assays .

• Substrate quality: The chemically synthesized Gn-PDol substrate quality is critical. The research showed that Gn-PDol (C95) was suitable as a substrate for ALG13/14 GnTase .

• Reaction conditions: The standard reaction mixture composition (Tris/HCl buffer, NP-40 detergent, glycerol, substrates) must be precisely controlled . Small variations in pH, temperature, or buffer composition can affect enzymatic activity.

• Incubation time and temperature: The research performed incubations at 37°C, but the optimal time may vary depending on enzyme concentration and experimental goals .

• Analysis methods: The hydrolysis step and LC-MS analysis parameters can affect quantification . Consistent sample preparation and analytical conditions are essential for reliable results.

• Negative controls: Include appropriate negative controls, such as boiled enzyme preparations, to establish baseline measurements and confirm the specificity of the observed activity .